Cinda Biotech (01801) shareholders deposit shares in Hong Kong and Shanghai HSBC with a market value of HK$4.598 billion

The Zhitong Finance App learned that the latest data from the Hong Kong Stock Exchange shows that on December 24, Cinda Biotech (01801) shareholders deposited shares with the Hong Kong and Shanghai HSBC Bank, with a market value of HK$4.598 billion, accounting for 3.31%.

UBS released a research report stating that Cinda Biotech's six new products and new indications of Cindilizumab have been included in the latest edition of the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)”. Furthermore, Cinda Biotech has been officially included in the Hang Seng Index. UBS maintains its “buy” rating with a target price of HK$137.4.